My SciELO
Services on Demand
Journal
Article
Indicators
- Cited by SciELO
- Access statistics
Related links
- Cited by Google
- Similars in SciELO
- Similars in Google
Share
Medicina Intensiva
Print version ISSN 0210-5691
Abstract
MUNOZ-SANCHEZ, A. and MURILLO-CABEZAS, F.. Tranexamic acid therapy decreases mortality of traumatic hemorrhagic shock. Med. Intensiva [online]. 2011, vol.35, n.5, pp.286-287. ISSN 0210-5691.
The CRASH 2, a randomized, double-blind, controlled trial, that enrolled 20,211 adult trauma patients, has shown that the administration of tranexamic acid significantly reduces all-cause mortality and that specifically associated with severe blood loss as well. We consider it a significant therapeutic advance, because, for the first time, a drug has been demonstrated to safely diminish mortality due to traumatic bleeding shock. On the basis of these results, and the high rate of death due to traumatic bleeding, we suggest that tranexamic acid should be considered for compassionate use in bleeding trauma patients prior to its definitive approval for this medical condition.
Keywords : Tranexamic acid; Traumatism; Traumatic bleeding shock.